Toa Eiyo
TOA EIYO is a research and development oriented pharmaceutical company specializing in cardiovascular and related fields. Established in 1943, it has a history of producing vitamin B2 formulations and innovative cardiovascular medicines. The company aims to contribute to society by developing new medicines and generic drugs, supporting health, and addressing the needs of an aging society. It is committed to high-quality drug production, ethical standards, and continuous innovation in medical treatment.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Transdermal beta-1 blocker patch
Transdermal formulation of a beta-1 adrenergic blocker for hypertension and atrial fibrillation management.
Transdermal isosorbide dinitrate patch
Transdermal nitrate preparation for the treatment of ischemic heart disease.
Oral isosorbide dinitrate and mononitrate tablets
Oral nitrate formulations for angina pectoris and ischemic heart disease.
Metered-dose nitroglycerin sublingual spray and nitroglycerin injectables
Rapid-onset nitroglycerin formulations for acute management of angina and related conditions.
Oral and injectable anti-arrhythmic agents
Various anti-arrhythmic drug formulations provided in oral and injectable forms for cardiac arrhythmia management.
Cardiac glycoside and heart-failure related oral therapies
Oral cardiac glycosides, loop diuretics and other oral therapies for heart failure management.
Transdermal beta-1 blocker patch
Transdermal formulation of a beta-1 adrenergic blocker for hypertension and atrial fibrillation management.
Transdermal isosorbide dinitrate patch
Transdermal nitrate preparation for the treatment of ischemic heart disease.
Oral isosorbide dinitrate and mononitrate tablets
Oral nitrate formulations for angina pectoris and ischemic heart disease.
Metered-dose nitroglycerin sublingual spray and nitroglycerin injectables
Rapid-onset nitroglycerin formulations for acute management of angina and related conditions.
Oral and injectable anti-arrhythmic agents
Various anti-arrhythmic drug formulations provided in oral and injectable forms for cardiac arrhythmia management.
Cardiac glycoside and heart-failure related oral therapies
Oral cardiac glycosides, loop diuretics and other oral therapies for heart failure management.
Services
End-to-end production and commercial distribution of prescription pharmaceuticals across oral, transdermal and parenteral dosage forms.
Collaborative R&D, licensing and partnership agreements for development and distribution of therapeutic products, particularly in the cardiovascular area.
Operational processes for conducting clinical studies, protecting volunteer rights, and collecting/evaluating scientific data to support product safety and proper use.
Technical development of transdermal delivery systems and tablet formulations supported by dedicated R&D centers and formulation expertise.
End-to-end production and commercial distribution of prescription pharmaceuticals across oral, transdermal and parenteral dosage forms.
Collaborative R&D, licensing and partnership agreements for development and distribution of therapeutic products, particularly in the cardiovascular area.
Operational processes for conducting clinical studies, protecting volunteer rights, and collecting/evaluating scientific data to support product safety and proper use.
Technical development of transdermal delivery systems and tablet formulations supported by dedicated R&D centers and formulation expertise.
Expertise Areas
- Cardiovascular drug development
- Transdermal drug delivery
- Oral and parenteral formulation development
- Fermentation and bioprocessing
Key Technologies
- Transdermal drug delivery systems (patches, tapes)
- Oral tablet formulation (including OD tablets)
- Parenteral/injectable formulation
- Metered-dose sublingual spray formulation